Continuous Glucose Monitoring Will Redefine Preventive Diabetes Care

Published
28 Mar 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$1.41
67.6% undervalued intrinsic discount
15 Aug
US$0.46
Loading
1Y
8.9%
7D
-3.2%

Author's Valuation

US$1.4

67.6% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on08 Aug 25
Fair value Decreased 8.87%

The downward revision in Senseonics Holdings’ price target reflects a combination of lowered future earnings multiples and a higher discount rate, resulting in the consensus fair value estimate declining from $1.55 to $1.41. What's in the News Senseonics Holdings completed a $50 million follow-on equity offering, issuing 100 million common shares at $0.50 per share with a $0.03 discount.

Shared on01 May 25

Shared on24 Apr 25
Fair value Decreased 13%

Shared on17 Apr 25
Fair value Increased 5.95%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 8.39%

AnalystConsensusTarget has decreased revenue growth from 53.7% to 38.3%, increased future PE multiple from 167.2x to 202.9x and decreased shares outstanding growth rate from 0.2% to 0.1%.